Literature DB >> 19543326

Unrelated umbilical cord blood transplantation in children with immune deficiency: results of a multicenter study.

H Frangoul1, L Wang, F E Harrell, B Manes, C Calder, J Domm.   

Abstract

In the absence of a related donor, unrelated cord blood transplant (CBT) may be a potential option for patients with a primary immune deficiency (PID). Most published experience consists of single-center data using multiple preparative regimens and GVHD prophylaxis. We report the results of a multicenter prospective trial of unrelated CBT for PID. A total of 24 children with PID, with a median age of 1 year (range: 0.23-7.81 years) and a median weight of 10.5 kg (range: 4-24.4 kg) received unrelated CBT between 1999 and 2003. All patients received a fully ablative conditioning regimen with identical GVHD prophylaxis and supportive care. Most patients (79%) received a 1 or 2 HLA Ag-mismatched cord unit with a median nucleated cell infused of 9.3 x 10(7)/kg (range: 1.0-31.2) and a median CD34 of 2.7 x 10(5)/kg 2.9 (range: 0.6-84.5). The cumulative incidence of neutrophil engraftment by day 42 was 58% (95% CI: 38-79%) at a median of 19 days. Cumulative incidence estimates of grade III-IV acute GVHD at day 100 and chronic GVHD at 1 year were 29% (95% CI: 10-48%) and 24% (95% CI: 3-44%), respectively. The probability of survival at 180 days and 1 year was 66.7% (95% CI: 44.3-81.7%) and 62.5% (95% CI: 40.3-78.4%), respectively. Unrelated CBT should be considered in children with PID.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19543326     DOI: 10.1038/bmt.2009.137

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  7 in total

1.  Future alternative therapies for β-thalassemia.

Authors:  Stefano Rivella; Eliezer Rachmilewitz
Journal:  Expert Rev Hematol       Date:  2009-12-01       Impact factor: 2.929

Review 2.  Umbilical cord blood banking: an update.

Authors:  Merlin G Butler; Jay E Menitove
Journal:  J Assist Reprod Genet       Date:  2011-05-27       Impact factor: 3.412

3.  The Mannheim Cord Blood Bank: Experiences and Perspectives for the Future.

Authors:  Stephanie Lauber; Monika Latta; Harald Klüter; Michael Müller-Steinhardt
Journal:  Transfus Med Hemother       Date:  2010-03-15       Impact factor: 3.747

4.  Allogeneic Hematopoietic Cell Transplantation in Patients with Primary Immunodeficiencies in Korea: Eleven-Year Experience in a Single Center.

Authors:  Eun Sang Yi; Young Bae Choi; Na Hee Lee; Ji Won Lee; Ki Woong Sung; Hong Hoe Koo; Eun-Sook Kang; Yae-Jean Kim; Keon Hee Yoo
Journal:  J Clin Immunol       Date:  2018-08-27       Impact factor: 8.317

5.  A novel reduced-intensity conditioning regimen for unrelated umbilical cord blood transplantation in children with nonmalignant diseases.

Authors:  Suhag H Parikh; Adam Mendizabal; Cara L Benjamin; Krishna V Komanduri; Jeyaraj Antony; Aleksandra Petrovic; Gregory Hale; Timothy A Driscoll; Paul L Martin; Kristin M Page; Ketti Flickinger; Jerelyn Moffet; Donna Niedzwiecki; Joanne Kurtzberg; Paul Szabolcs
Journal:  Biol Blood Marrow Transplant       Date:  2013-12-01       Impact factor: 5.742

Review 6.  Umbilical Cord Blood Banking for Transplantation in Morocco: Problems and opportunities.

Authors:  Loubna Mazini; Nourredine Matar; Said Bouhya; Diaa Marzouk; Wagida Anwar; Meriem Khyatti
Journal:  J Stem Cells Regen Med       Date:  2014-11-28

7.  Low-dose serotherapy improves early immune reconstitution after cord blood transplantation for primary immunodeficiencies.

Authors:  Jonathan P Lane; Philippa T G Evans; Zohreh Nademi; Dawn Barge; Anthony Jackson; Sophie Hambleton; Terry J Flood; Andrew J Cant; Mario Abinun; Mary A Slatter; Andrew R Gennery
Journal:  Biol Blood Marrow Transplant       Date:  2013-11-10       Impact factor: 5.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.